Literature DB >> 7508321

Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.

.   

Abstract

This paper is the complete protocol (Manual of Operations) used in the Central Vein Occlusion Study (CVOS). The CVOS is a randomized clinical trial and natural history study of central retinal vein occlusion supported by the National Eye Institute. The administrative structure includes a Data and Safety Monitoring Board, 9 clinical centers, a coordinating center, and a photograph reading center. The Manual of Operations describes study design, organization, policies, and procedures. Procedures described in detail include measurement of visual acuity, fundus and iris photography, fluorescein angiography, and quality control.

Entities:  

Mesh:

Year:  1993        PMID: 7508321

Source DB:  PubMed          Journal:  Online J Curr Clin Trials        ISSN: 1059-2725


  4 in total

1.  A "throttle" mechanism in the central retinal vein in the region of the lamina cribrosa.

Authors:  Tom H Williamson
Journal:  Br J Ophthalmol       Date:  2006-09-27       Impact factor: 4.638

2.  Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.

Authors:  Barbara A Blodi; Amitha Domalpally; Ingrid U Scott; Michael S Ip; Neal L Oden; Julee Elledge; Kelly Warren; Michael M Altaweel; Judy E Kim; Paul C Van Veldhuisen
Journal:  Arch Ophthalmol       Date:  2010-09

3.  [Cytokine determination from vitreous samples in retinal vascular diseases].

Authors:  M Pfister; F H Koch; J Cinatl; F Rothweiler; R Schubert; P Singh; H Ackermann; M J Koss
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

4.  Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases.

Authors:  H C Hasselbach; F Ruefer; N Feltgen; U Schneider; S Bopp; L L Hansen; H Hoerauf; U Bartz-Schmidt; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08       Impact factor: 3.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.